Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide

European Journal of Haematology

Volumn 95, Issue 1, 2015, Pages 35-43

  Merkerova, Michaela Dostalova ^a   Krejcik, Zdenek ^a   Belickova, Monika ^a   Hrustincova, Andrea ^a   Klema, Jiri ^b   Stara, Eliška ^a   Zemanova, Zuzana ^c   Michalova, Kyra ^a,c   Cermak, Jaroslav ^a   Jonasova, Anna ^d  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CZECH TECHNICAL UNIVERSITY IN PRAGUE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Del(5q); Lenalidomide; MiRNA; Myelodysplastic syndromes

Indexed keywords

CD14 ANTIGEN; LENALIDOMIDE; MICRORNA; MICRORNA 127 3P; MICRORNA 143; MICRORNA 145; MICRORNA 146A; MICRORNA 154; MICRORNA 15A; MICRORNA 196B; MICRORNA 210; MICRORNA 212; MICRORNA 224; MICRORNA 27B; MICRORNA 323 3P; MICRORNA 34A; MICRORNA 34B; MICRORNA 378; MICRORNA 431; MICRORNA 451; MICRORNA 487B; MICRORNA 493; MICRORNA 495; MICRORNA 496; MICRORNA 589; MICRORNA 874; MICRORNA 98; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; MIRN196 MICRORNA, HUMAN; MIRN34 MICRORNA, HUMAN; MIRN378 MICRORNA, HUMAN; MIRN451 MICRORNA, HUMAN; THALIDOMIDE;

5Q- SYNDROME; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; GENE EXPRESSION PROFILING; HEMATOPOIESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IN VIVO STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANEMIA, MACROCYTIC; CASE CONTROL STUDY; CHROMOSOME 14; CHROMOSOME 5; CHROMOSOME DELETION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE LOCUS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HAPLOINSUFFICIENCY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PRIMARY CELL CULTURE; RNA SPLICING; SIGNAL TRANSDUCTION;

AGED; ANEMIA, MACROCYTIC; CASE-CONTROL STUDIES; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC LOCI; GENOME-WIDE ASSOCIATION STUDY; HAPLOINSUFFICIENCY; HUMANS; IMMUNOLOGIC FACTORS; LEUKOCYTES, MONONUCLEAR; MALE; MICRORNAS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PRIMARY CELL CULTURE; RNA SPLICING; SIGNAL TRANSDUCTION; THALIDOMIDE;

EID: 84931360220     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12458     Document Type: Article

References (42)

1. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974;251:437-8.
2. Mallo M, Cervera J, Schanz J, et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia 2011;25:110-20.
3. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009;2:36.
4. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-65.
5. Fenaux P, Giagounidis A, Selleslag D, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011;118:3765-76.
6. Boultwood J, Fidler C, Strickson AJ, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 2002;99:4638-41.
7. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008;451:335-9.
8. Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A 2007;104:11406-11.
9. Oliva EN, Cuzzola M, Nobile F, et al. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion. Eur J Haematol 2010;85:231-5.
10. Belickova M, Cermak J, Dostalova Merkerova M, et al. Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q). Clin Lymphoma Myeloma Leuk 2012;12:375-83.
11. Oliva EN, Cuzzola M, Aloe Spiriti MA, et al. Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study. Ann Hematol 2013;92:25-32.
12. Hussein K, Theophile K, Busche G, Schlegelberger B, Gohring G, Kreipe H, Bock O. Aberrant microRNA expression pattern in myelodysplastic bone marrow cells. Leuk Res 2010;34:1169-74.
13. Votavova H, Grmanova M, Dostalova Merkerova M, Belickova M, Vasikova A, Neuwirtova R, Cermak J. Differential expression of microRNAs in CD34+ cells of 5q- syndrome. J Hematol Oncol 2011;4:1-8722.
14. Dostalova Merkerova M, Krejcik Z, Votavova H, Belickova M, Vasikova A, Cermak J. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet 2011;19:313-9.
15. Starczynowski DT, Morin R, McPherson A, et al. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood 2011;117:595-607.
16. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010;16:49-58.
17. Neuwirtova R, Fuchs O, Holicka M, et al. Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond-Blackfan anemia. Ann Hematol 2013;92:11-8.
18. Kumar MS, Narla A, Nonami A, et al. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood 2011;118:4666-73.
19. Venner CP, Woltosz JW, Nevill TJ, et al. Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome. Haematologica 2013;98:409-13.
20. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic sydromes. Blood 2000;96:3671-4.
21. Shaffer LG, McGowan-Jordan J, Schmid M (eds). ISCN (2013): An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger, 2013.
22. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-8.
24. Hermeking H. p53 enters the microRNA world. Cancer Cell 2007;12:414-8.
25. Chang TC, Wentzel EA, Kent OA, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007;26:745-52.
26. Wang X, Liu P, Zhu H, Xu Y, Ma C, Dai X, Huang L, Liu Y, Zhang L, Qin C. miR-34a, a microRNA up-regulated in a double transgenic mouse model of Alzheimer's disease, inhibits bcl2 translation. Brain Res Bull 2009;80:268-73.
27. Fabbri M, Bottoni A, Shimizu M, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011;305:59-67.
28. Zenz T, Mohr J, Eldering E, et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009;113:3801-8.
29. Wong MY, Yu Y, Walsh WR, Yang JL. microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review). Int J Oncol 2011;38:1189-95.
30. Li Z, Huang H, Chen P, et al. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun 2012;3:688.
31. Schotte D, Lange-Turenhout EA, Stumpel DJ, Stam RW, Buijs-Gladdines JG, Meijerink JP, Pieters R, Den Boer ML. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia. Haematologica 2010;95:1675-82.
32. Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT. Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol 2007;35:1657-67.
33. Ebert BL, Galili N, Tamayo P, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008;5:e35.
34. Lopotová T, Záčková M, Klamová H, Moravcová J. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop? Leuk Res 2011;35:974-7.
35. Qi J, Qiao Y, Wang P, Li S, Zhao W, Gao C. microRNA-210 negatively regulates LPS-induced production of proinflammatory cytokines by targeting NF-κB1 in murine macrophages. FEBS Lett 2012;586:1201-7.
36. Dixon-McIver A, East P, Mein CA, Cazier JB, Molloy G, Chaplin T, Andrew Lister T, Young BD, Debernardi S. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS ONE 2008;3:e2141.
37. Choong ML, Yang HH, McNiece I. MicroRNA expression profiling during human cord blood-derived CD34 cell erythropoiesis. Exp Hematol 2007;35:551-64.
38. Leucci E, Onnis A, Cocco M, et al. B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. Int J Cancer 2010;126:1316-26.
39. Sternberg A, Killick S, Littlewood T, et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 2005;106:2982-91.
40. Seitz H, Royo H, Bortolin ML, Lin SP, Ferguson-Smith AC, Cavaille J. A large imprinted microRNA gene cluster at the mouse Dlk1-Gtl2 domain. Genome Res 2004;14:1741-8.
41. Boultwood J, Pellagatti A, Cattan H, et al. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol 2007;139:578-89.
42. Erdogan B, Facey C, Qualtieri J, et al. Diagnostic microRNAs in myelodysplastic syndrome. Exp Hematol 2011;39:915-26.